|
- IRMS - Nicolae Testemitanu SUMPh
- 1. COLECȚIA INSTITUȚIONALĂ
- Congresul consacrat aniversării a 75-a de la fondarea Universității de Stat de Medicină și Farmacie „Nicolae Testemițanu” din Republica Moldova
- Culegere de postere
Please use this identifier to cite or link to this item:
http://hdl.handle.net/20.500.12710/12853
Full metadata record
DC Field | Value | Language |
dc.contributor.author | Podgornii, Ana | - |
dc.contributor.author | Valica, Vladimir | - |
dc.contributor.author | Pogrebnoi, Serghei | - |
dc.contributor.author | Lupascu, Lucian | - |
dc.contributor.author | Uncu, Andrei | - |
dc.contributor.author | Macaev, Fliur | - |
dc.date.accessioned | 2020-11-11T07:40:18Z | - |
dc.date.available | 2020-11-11T07:40:18Z | - |
dc.date.issued | 2020-10 | - |
dc.identifier.uri | https://stiinta.usmf.md/ro/manifestari-stiintifice/zilele-universitatii | - |
dc.identifier.uri | http://repository.usmf.md/handle/20.500.12710/12853 | - |
dc.description | Department of Pharmaceutical and Toxicological Chemistry, Drug Scientific Center Nicolae Testemitanu State University of Medicine and Pharmacy, Chisinau, the Republic of Moldova, Laboratory of Organic Synthesis and Biopharmaceuticals, Institute of Chemistry, Chisinau, the Republic of Moldova, Congresul consacrat aniversării a 75-a de la fondarea Universității de Stat de Medicină și Farmacie „Nicolae Testemițanu” din Republica Moldova, Ziua internațională a științei pentru pace și dezvoltare | en_US |
dc.description.abstract | Introduction.
The therapeutic options in invasive candidiasis and aspergillosis are limited and don’t provide expected
results. Introducing a new drug in the therapeutic practice can improve the quality of life of
immunocompromised patients. The compound have poor solubility in polar
solvents (water, methanol, ethanol, acetonitrile,
acetone) and low bioavailability that limits the use
as antitubercular agent. But, presence of the azole
ring (pharmacophore group of azole antimycotic
drug) suggests that the studied substance may have
antimycotic activity. Purpose. The aim is to study the antimycotic activity of new substance phenoxithiazolchloralum (MF0010) on Aspergillus spp., Candida albicans, and Saccharomyces cerevisiae. Material and methods. Aspergillus spp.
For the evaluating of the antifungal activity of the
phenoxythiazolchloralum compound against Aspergillus spp. it
was used the microdilution method described by E. Stingaci et
al.(Stingaci E, Zveaghinteva M, Pogrebnoi S, Lupascu L, Valica V, Uncu
L, Smetanscaia A, Drumea M, Petrou A, Ciric A, Glamoclija J, Sokovic M, Kravtsov
V, Geronikaki A, Macaev F. New vinyl-1,2,4-triazole derivatives as antimicrobial
agents: Synthesis, biological evaluation and molecular docking studies. Bioorganic &
Medicinal Chemistry Letters. 2020;30(17). DOI:10.1016/j.bmcl.2020.127368). Candida albicans and Saccharomyces cerevisiae
For the evaluating of the antifungal activity for Candida
albicans, and Saccharomyces cerevisiae was used the
successive double dilution method (NCCLS M27). Results. For the first time, it was studied in vitro susceptibility of MF-0010 against A. fumigatus, A. versicolor, A.
ochramensis and A. niger. The MIC and MFC values of MF-0010 against Aspergillus spp. ranged from 0.23μM/ml –
0.62μM/ml and 0,62μM/ml –1.24μM/ml, respectively. The highest values of MIC and MCF of MF-0010 is related to
A. niger. Thus, the use of MF-0010 against this pathogen is not appropriate. With at least 0.05 μM/ml difference of MICs from
standards, MF-0010 can be considered quite more potent
than ketoconazole and bifonazole. The MIC/MCF ratios of MF-0010 for inhibition of Candida
albicans, Saccharomyces cerevisiae of are lower than nistatine
ones with 0.08 μMol for both pathogens. Thus, we can conclude
that MF-0010 is more potent active molecule than nistatine
against Candida albicans. Conclusions. In this study, we found that all analyzed pathogens were susceptible to MF-0010. According to experimental data, the
antimycotic activity of MF-0010 is quite better than the standards one. The MIC and MCF values of MF-0010 show a
good potency against Candida albicans, and new studies are warranted in order to design optimized formulations, to
analyse in vivo efficacy and quality assurance of formulations. | en_US |
dc.language.iso | en | en_US |
dc.publisher | Universitatea de Stat de Medicină şi Farmacie "Nicolae Testemiţanu" | en_US |
dc.subject | Phenoxythazolchloralum | en_US |
dc.subject | Aspergillus spp. | en_US |
dc.subject | Candida albicans | en_US |
dc.subject | Saccharomyces cerevisiae | en_US |
dc.subject | drug discovery | en_US |
dc.title | Antimycotic activity of phenoxythiazolchloralum | en_US |
dc.type | Other | en_US |
Appears in Collections: | Culegere de postere
|
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.
|